Clinical Trial Update: Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.

View source ↗

Summary

This study evaluates anti-Xa activity after subcutaneous enoxaparin for antithrombotic prophylaxis in severely obese patients, comparing two injection sites.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Venous Thromboembolism

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Venous Thromboembolism, Obese Patients | Status: NOT_YET_RECRUITING